

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

[HCCC-9810](#)

RRID:CVCL_6908

Type: Cell Line

Proper Citation

RRID:CVCL_6908

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_6908

Proper Citation: RRID:CVCL_6908

Description: Cell line HCCC-9810 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Intrahepatic cholangiocarcinoma

Defining Citation: [PMID:23505090](#), [PMID:23646150](#), [PMID:35640676](#)

Comments: Population: Chinese.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCCC-9810

Synonyms: HCCC9810, Hccc9810

Cross References: CCRID:1101HUM-PUMC000278, GEO:GSM936756, GEO:GSM1374514, Wikidata:Q54881836

ID: CVCL_6908

Record Creation Time: 20220427T220320+0000

Record Last Update: 20260905T180221+0000

Ratings and Alerts

No rating or validation information has been found for HCCC-9810.

No alerts have been found for HCCC-9810.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhong Y, et al. (2026) HERV2365 upregulates FGF1 expression by sponging miR-326 to promote the progression of intrahepatic cholangiocarcinoma. *iScience*, 29(6), 115852.

Lin Y, et al. (2026) Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma. *Cell reports. Medicine*, 7(4), 102708.

Wang F, et al. (2026) MYC-Mediated Functional Manifestation of IDH1 Mutations in Intrahepatic Cholangiocarcinoma Confers Sensitivity to (+)-JQ1. *International journal of biological sciences*, 22(5), 2247.

Cai D, et al. (2026) L-lactate-driven PSMD14 lactylation and stabilization promote lactate production and ferroptosis resistance via ENO1 in intrahepatic cholangiocarcinoma. *Cancer letters*, 646, 218394.

Luo G, et al. (2025) Platelets promote metastasis of intrahepatic cholangiocarcinoma through activation of TGF- β /Smad2 pathway. *Biochimica et biophysica acta. Molecular basis of disease*, 1871(4), 167734.

Dong L, et al. (2022) Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. *Cancer cell*, 40(1), 70.

Liu Z, et al. (2022) Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma. *Oncology reports*, 48(3).

Hao X, et al. (2021) STK39 enhances the progression of Cholangiocarcinoma via PI3K/AKT pathway. *iScience*, 24(11), 103223.